 CAMBRIDGE, Mass., July 26, 2021 PRNewswire -- Leap Therapeutics, Inc. Nasdaq:LPTX, a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting initial data from the DisTinGuish study, a Phase 2a clinical trial evaluating Leaps anti-Dickkopf-1 DKK1 antibody, DKN-01, in combination with tislelizumab, BeiGenes Ltd. 